Cargando…

Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice

The use of an aromatase inhibitor (AI) in combination with ovarian function suppression (OFS) has become the mainstay of adjuvant endocrine therapy in high-risk premenopausal patients with hormone receptor-positive breast cancer. Although five years of such therapy effectively reduces recurrence rat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buono, Giuseppe, Arpino, Grazia, Del Mastro, Lucia, Fabi, Alessandra, Generali, Daniele, Puglisi, Fabio, Zambelli, Alberto, Cinieri, Saverio, Nuzzo, Francesco, Di Lauro, Vincenzo, Vigneri, Paolo, Bianchini, Giampaolo, Montemurro, Filippo, Gennari, Alessandra, De Laurentiis, Michelino
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9645191/ https://www.ncbi.nlm.nih.gov/pubmed/36387212 http://dx.doi.org/10.3389/fonc.2022.1032166

Ejemplares similares

Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach
por: Fabi, Alessandra, et al.
Publicado: (2022)

An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project
por: Pelizzari, Giacomo, et al.
Publicado: (2018)

Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests
por: Saponaro, Mariarosaria, et al.
Publicado: (2022)

Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review
por: Garutti, Mattia, et al.
Publicado: (2022)

Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study
por: Di Maio, Massimo, et al.
Publicado: (2023)

Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations
por: D’Arienzo, Andrea, et al.
Publicado: (2023)

Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives
por: Agostinetto, Elisa, et al.
Publicado: (2022)

Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis
por: Schettini, Francesco, et al.
Publicado: (2021)

CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
por: Schettini, Francesco, et al.
Publicado: (2018)

Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review
por: Di Lauro, V., et al.
Publicado: (2022)

T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study
por: Schettini, F., et al.
Publicado: (2021)

Efficacy and safety of T-DM1 in the ‘common-practice’ of HER2+ advanced breast cancer setting: a multicenter study
por: Fabi, Alessandra, et al.
Publicado: (2017)

Improved adjuvant endocrine therapy for premenopausal women with endocrine responsive disease
por: Goldhirsch, Aron, et al.
Publicado: (2015)

Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2− Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study
por: De Laurentiis, Michelino, et al.
Publicado: (2022)

Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies
por: Lambertini, Matteo, et al.
Publicado: (2023)

Adjuvant endocrine therapy for premenopausal women with early breast cancer
por: Bao, Ting, et al.
Publicado: (2007)

Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
por: Piezzo, Michela, et al.
Publicado: (2020)

Supportive therapies in the prevention of chemotherapy-induced febrile neutropenia and appropriate use of granulocyte colony-stimulating factors: a Delphi consensus statement
por: Adamo, Vincenzo, et al.
Publicado: (2022)

Endocrinology and hormone therapy in breast cancer: Endocrine therapy in premenopausal women
por: Pritchard, Kathleen
Publicado: (2005)

Emetogenicity of Antibody-Drug Conjugates (ADCs) in Solid Tumors with a Focus on Trastuzumab Deruxtecan: Insights from an Italian Expert Panel
por: Bianchini, Giampaolo, et al.
Publicado: (2022)

Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer
por: Forward, D P, et al.
Publicado: (2004)

Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives
por: Cocco, Stefania, et al.
Publicado: (2020)

A dose-comparative endocrine-clinical study of leuprorelin in premenopausal breast cancer patients.
por: Dowsett, M., et al.
Publicado: (1990)

The 6th Milan Breast Cancer Conference, Milan, Italy, 16–18 June 2004
por: Gennari, Roberto, et al.
Publicado: (2005)

The role of taxanes in triple-negative breast cancer: literature review
por: Mustacchi, Giorgio, et al.
Publicado: (2015)

Rare tumours of the breast
por: Esposito, Emanuela, et al.
Publicado: (2019)

Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer
por: Puglisi, Fabio, et al.
Publicado: (2021)

Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors
por: Piezzo, Michela, et al.
Publicado: (2020)

Targeting Autophagy in Breast Cancer
por: Cocco, Stefania, et al.
Publicado: (2020)

Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis
por: De Angelis, Carmine, et al.
Publicado: (2017)

Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer.
por: Bianco, A. R., et al.
Publicado: (1991)

The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer.
por: Stein, R. C., et al.
Publicado: (1990)

Health belief about adjuvant endocrine therapy in premenopausal breast cancer survivors: a qualitative study
por: Xu, Lei, et al.
Publicado: (2019)

Adjuvant endocrine therapy for premenopausal women with breast cancer: Patient adherence and physician prescribing practices in Mexico
por: Villarreal-Garza, Cynthia, et al.
Publicado: (2021)

Endocrine Actions of Osteocalcin
por: Patti, Aurora, et al.
Publicado: (2013)

Premenopausal osteoporosis
por: Cheng, Marilyn Lee, et al.
Publicado: (2013)

Male Breast Cancer: From Molecular Genetics to Clinical Management
por: Pensabene, Matilde, et al.
Publicado: (2022)

Contraceptive Use in Premenopausal Women With Early Breast Cancer
por: Lambertini, Matteo, et al.
Publicado: (2022)

Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?
por: Lambertini, Matteo, et al.
Publicado: (2018)

Comparison of changes in lipid profiles of premenopausal women with early-stage breast cancer treated with different endocrine therapies
por: Wang, Kaiyue, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7gv1bhjihddf7qa04u0d38vilt